share_log

Mangoceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Mangoceuticals | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Mangoceuticals | S-1/A:證券上市註冊聲明(修正)
美股SEC公告 ·  05/06 17:36

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc. has reported its financial performance for the year ended December 31, 2023, with revenues totaling $731,493 and a net loss of $9,212,417. The company's accumulated deficit has reached $11,228,173. Earlier in the year, Mangoceuticals completed an initial public offering (IPO) in March, raising approximately $4.35 million by issuing 1,250,000 shares at $4.00 each. Additionally, a follow-on offering was conducted, involving the sale of 4,600,000 shares and the issuance of warrants to Boustead Securities, LLC. The company has also entered into consulting agreements, compensating with restricted common stock, and borrowed funds from entities controlled by CEO Jacob D. Cohen, with the borrowed amounts being payable on demand without interest. Furthermore, stockholders have approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for awards. Despite the financial challenges, as indicated by the substantial doubt about the company's ability to continue as a going concern, Mangoceuticals has prepared its financial statements on a going concern basis and is not currently involved in any litigation that could impact its operations.
Mangoceuticals, Inc. has reported its financial performance for the year ended December 31, 2023, with revenues totaling $731,493 and a net loss of $9,212,417. The company's accumulated deficit has reached $11,228,173. Earlier in the year, Mangoceuticals completed an initial public offering (IPO) in March, raising approximately $4.35 million by issuing 1,250,000 shares at $4.00 each. Additionally, a follow-on offering was conducted, involving the sale of 4,600,000 shares and the issuance of warrants to Boustead Securities, LLC. The company has also entered into consulting agreements, compensating with restricted common stock, and borrowed funds from entities controlled by CEO Jacob D. Cohen, with the borrowed amounts being payable on demand without interest. Furthermore, stockholders have approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for awards. Despite the financial challenges, as indicated by the substantial doubt about the company's ability to continue as a going concern, Mangoceuticals has prepared its financial statements on a going concern basis and is not currently involved in any litigation that could impact its operations.
Mangoceuticals, Inc.公佈了截至2023年12月31日止年度的財務業績,收入總額爲731,493美元,淨虧損爲9,212,417美元。該公司的累計赤字已達到11,228,173美元。今年早些時候,Mangoceuticals於3月完成了首次公開募股(IPO),以每股4.00美元的價格發行了125萬股股票,籌集了約435萬澳元。此外,還進行了後續發行,包括出售4,600,000股股票和向Boustead Securities, LLC發行認股權證。該公司還簽訂了諮詢協議,以限制性普通股進行補償,並向首席執行官雅各布·科恩控制的實體借入資金,借款金額可按需支付,無需支付利息。此外,股東已經批准了2022年股權激勵計劃的修正案,增加了可供獎勵的股票數量。儘管面臨財務挑戰,但正如人們對公司繼續經營能力的重大懷疑所表明的那樣,Mangoceuticals仍在持續經營的基礎上編制了財務報表,目前沒有參與任何可能影響其運營的訴訟。
Mangoceuticals, Inc.公佈了截至2023年12月31日止年度的財務業績,收入總額爲731,493美元,淨虧損爲9,212,417美元。該公司的累計赤字已達到11,228,173美元。今年早些時候,Mangoceuticals於3月完成了首次公開募股(IPO),以每股4.00美元的價格發行了125萬股股票,籌集了約435萬澳元。此外,還進行了後續發行,包括出售4,600,000股股票和向Boustead Securities, LLC發行認股權證。該公司還簽訂了諮詢協議,以限制性普通股進行補償,並向首席執行官雅各布·科恩控制的實體借入資金,借款金額可按需支付,無需支付利息。此外,股東已經批准了2022年股權激勵計劃的修正案,增加了可供獎勵的股票數量。儘管面臨財務挑戰,但正如人們對公司繼續經營能力的重大懷疑所表明的那樣,Mangoceuticals仍在持續經營的基礎上編制了財務報表,目前沒有參與任何可能影響其運營的訴訟。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息